Page 32 - Amgen News Today

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading...

One of these ETFs recently yielded a hefty 6.5%. Several have averaged double-digit annual growth over the past 5 and 10 years.

We want to see your mother, your grandmother and your aunt all living their best lives. But osteoporosis is a silent disease that women...

Steward Partners Investment Advisory LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 70,559 shares of the medical research company’s stock after buying an additional 3,077 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Amgen were worth $20,322,000 […]

24/7 Wall Street Insights The Dow Jones Industrial Average recently cracked 40,000 for an all-time new high. The 30 stocks that comprise the DJIA have not uniformly boosted the average at the same time. Amazon, Honeywell and Chevron are three Dow stocks that may have some sizable upside potential left for the remainder of 2024, […]

Stifel Financial Corp lifted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.2% in the fourth quarter, HoldingsChannel reports. The firm owned 1,358,181 shares of the medical research company’s stock after buying an additional 3,299 shares during the period. Stifel Financial Corp’s holdings in Amgen were worth $391,216,000 at the end of the […]

It takes an average of 17 years for scientific evidence to reach clinical practice. While cultivating evidence to improve care guidelines is paramount, the healthcare industry is recognizing the value in bridging the implementation gap between evidence-based guidelines and routine clinical

The U.S. Food and Drug Administration approved on Tuesday Amgens Bkemv, the first biosimilar to AstraZenecas rare blood disorder treatment Soliris. Amgens drug will be marketed under...

Evermay Wealth Management LLC raised its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 5.1% during the fourth quarter, Holdings Channel reports. The fund owned 2,541 shares of the medical research company’s stock after acquiring an additional 124 shares during the period. Evermay Wealth Management LLC’s holdings in Amgen were worth $732,000 as of […]